MERIBEL

OFFICIAL TITLE: MONOTHERAPY WITH ERIBULIN IN HER2 NEGATIVE METASTATIC BREAST CANCER AS A FIRST LINE TREATMENT.

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

ESMO 2016 - DOWNLOAD THE POSTER

SABCS 2014 - DOWNLOAD THE POSTER

CLINICAL TRIAL DETAILS

A PHASE IIA PROSPECTIVE, MULTICENTER, OPEN AND NOT CONTROLLED OF THE EFFICACY AND TOLERABILITY ON THE FIRST LINE TREATMENT WITH ERIBULIN AS A UNIC AGENT ON PATIENTS WITH HER2 NEGATIVE METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TAXANES.

MULTICENTRE, PROSPECTIVE, NON-CONTROLLED PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND TOLERABILITY OF FIRST LINE SINGLE AGENT ERIBULIN IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CARCINOMA PREVIOUSLY EXPOSED TO TAXANES FOR EARLY STAGE.

THE PRIMARY OBJECTIVE OF THE STUDY IS TO DETERMINE THE MEDIAN TIME TO PROGRESSION ACHIEVED WITH ERIBULIN. OTHER SECONDARY OBJECTIVES WILL BE; OVERALL RESPONSE RATE, CLINICAL BENEFIT RATE, TIME TO TREATMENT PROGRESSION, DURATION OF RESPONSE AND TOXICITY PROFILE.

MERIBEL AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

BREAST (Her2-)

II

53

13

Spain, Portugal

Closing

N

SITES

COUNTRY

STATUS

MERIBEL SITES

home_fondo_you_barra.jpg

SPAIN

Hospital Arnau de Vilanova de Valencia

SPAIN

Complejo Hospitalario Universitario A Coruña (CHUAC)

SPAIN

Hospital Universitario Miguel Servet

SPAIN

Hospital Universitario Central de Asturias (HUCA)

SPAIN

Complejo Asistencial Universitario de Salamanca

SPAIN

Hospital Universitario La Paz

SPAIN

Hospital Infanta Cristina

SPAIN

Hospital Universitari Vall D'Hebron

SPAIN

Hospital Sanitas La Moraleja

SPAIN

Complejo Hospitalario de Navarra

SPAIN

Hospital del Mar

SPAIN

Complejo Hospitalario Universitario Insular Materno Infantil

PORTUGAL

Instituto Portugues Oncologia de Porto (IPO)